BOTOX® Cosmetic  Unveils "The One & Only" Campaign Featuring Real People and Their Distinctive Stories

BOTOX® Cosmetic Unveils "The One & Only" Campaign Featuring Real People and Their Distinctive Stories

  • Building on the brand's 20-year legacy and real-world experience, the original BOTOX ® Cosmetic continues to be the most researched and requested product of its kind. 1,2
  • BOTOX® Cosmetic is trusted by aesthetic providers with 95% of specialists choosing it for themselves, their friends, and family. 3
  • This campaign is BOTOX ® Cosmetic's largest ever, appearing across national linear and connected TV, digital, social, and out-of-home.

- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced a new chapter for BOTOX ® Cosmetic with the debut of "The One & Only" campaign, a national, multichannel marketing initiative that champions self-expression and individuality. The one and only brand to do it first, BOTOX ® Cosmetic is the #1 selling neurotoxin worldwide with the most FDA-approved aesthetic indication areas in the category, empowering patients to embrace the one and only version of themselves. 2,4-9

The One & Only campaign features real, everyday people, both new and repeat patients, treated with BOTOX ® Cosmetic. The campaign depicts each person doing what they love, while showing off their individuality. The One & Only campaign demonstrates that patients are their same unique selves, even after treatment. The tagline for the campaign is, "The one & only BOTOX ® Cosmetic. The one & only you."

"Just as each person is distinct, so too are their aesthetic goals. As a champion of authenticity, Allergan Aesthetics' new campaign features real people, not actors, who rely on BOTOX ® Cosmetic's precise, predictable results," said Glen Curran , Senior Vice President, U.S., Allergan Aesthetics. "When it comes to being yourself and choosing treatment with BOTOX ® Cosmetic, there's no substitute for the real thing. The one and only BOTOX ® Cosmetic continues to empower patients throughout their treatment journey."

BOTOX ® Cosmetic is the product patients ask for by name and tell others about, with market research showing that 77 percent of treated consumers believe it is worth the cost. 11* It is also the product patients keep coming back for; 91 percent of patients say they will continue using BOTOX ® Cosmetic if their specialist says they are right for treatment. 12† Additionally, Cosmopolitan magazine recently recognized BOTOX ® Cosmetic as "Best Injectable" in the 2025 Cosmopolitan Readers' Choice Beauty Awards , with readers saying, "BOTOX ® Cosmetic continues to be the one you depend on; it's the one and only."

FDA-approved for more than 20 years, BOTOX ® Cosmetic continues to lead the market with more than 100 million vials sold globally. 4,10 The brand has four FDA-approved aesthetic indication areas, the most in the category, including moderate to severe frown lines, crow's feet lines, forehead lines, and vertical bands connecting the neck and jaw (platysma bands) in adults. 4

The One & Only campaign will run across national linear and connected television, digital, social, and out-of-home. Those interested in learning more about BOTOX ® Cosmetic and The One & Only campaign can visit botoxcosmetic.com and enroll in Allē , the leading aesthetics loyalty program from Allergan Aesthetics.

*Based on a 2023 online survey of 233 BOTOX ® Cosmetic users. 11

Based on a 2023 online survey of 258 BOTOX ® Cosmetic users who strongly or somewhat agreed they would continue receiving BOTOX ® Cosmetic treatment. 12

About Allergan Aesthetics
At Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. Our aesthetics portfolio includes facial injectables, body contouring, plastics, skin care, and more. Our goal is to consistently provide our customers with innovation, education, exceptional service, and a commitment to excellence, all with a personal touch. For more information, visit www.allerganaesthetics.com .

About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com . Follow @AbbVie on LinkedIn , Facebook , Instagram , X (formerly Twitter) , and YouTube .

IMPORTANT SAFETY INFORMATION

BOTOX ® Cosmetic may cause serious side effects that can be life threatening. Get medical help right away if you have any of these problems any time (hours to weeks) after injection of BOTOX ® Cosmetic:

  • Problems swallowing, speaking, or breathing, due to weakening of associated muscles, which can be severe and result in loss of life. You are at the highest risk if these problems are preexisting before injection. Swallowing problems may last for several months.
  • Spread of toxin effects. The effect of botulinum toxin may affect areas away from the injection site and cause serious symptoms, including loss of strength and all-over muscle weakness, double vision, blurred vision and drooping eyelids, hoarseness or change or loss of voice, trouble saying words clearly, loss of bladder control, trouble breathing, and trouble swallowing.

BOTOX ® Cosmetic dosing units are not the same as, or comparable to, any other botulinum toxin product.

There has not been a confirmed serious case of spread of toxin effect when BOTOX ® Cosmetic has been used at the recommended dose to treat frown lines, crow's feet lines, forehead lines, and/or platysma bands.

BOTOX ® Cosmetic may cause loss of strength or general muscle weakness, vision problems, or dizziness within hours to weeks of receiving BOTOX ® Cosmetic. If this happens, do not drive a car, operate machinery, or do other dangerous activities.

Serious and/or immediate allergic reactions have been reported, including itching, rash, red itchy welts, wheezing, asthma symptoms, or dizziness or feeling faint. Get medical help right away if you are wheezing or have asthma symptoms, or if you become dizzy or faint.

Do not receive BOTOX ® Cosmetic if you are allergic to any of the ingredients in BOTOX ® Cosmetic (see Medication Guide for ingredients); had an allergic reaction to any other botulinum toxin product such as Myobloc (rimabotulinumtoxinB), Dysport (abobotulinumtoxinA), Xeomin (incobotulinumtoxinA), Jeuveau (prabotulinumtoxinA-xvfs), Daxxify (daxibotulinumtoxinA-lanm), or Letybo (letibotulinumtoxinA-wlbg); or have a skin infection at the planned injection site. This list may not include all available botulinum toxin products.

Tell your doctor about all your muscle or nerve conditions, such as ALS or Lou Gehrig's disease, myasthenia gravis, or Lambert-Eaton syndrome, as you may be at increased risk of serious side effects, including difficulty swallowing and difficulty breathing, from standard doses of BOTOX ® Cosmetic.

Tell your doctor about all your medical conditions, including surgery or plans to have surgery on your face, trouble raising your eyebrows, drooping eyelids, any other abnormal facial change, are pregnant or plan to become pregnant (it is not known if BOTOX ® Cosmetic can harm your unborn baby), or are breastfeeding or plan to (it is not known if BOTOX ® Cosmetic passes into breast milk).

Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Using BOTOX ® Cosmetic with certain other medicines may cause serious side effects. Do not start any new medicines until you have told your doctor that you have received BOTOX ® Cosmetic in the past.

Tell your doctor if you have received any other botulinum toxin product in the last 4 months; have received injections of botulinum toxin such as Myobloc, Dysport, Xeomin, Jeuveau, Daxxify, or Letybo in the past (tell your doctor exactly which product you received); have recently received an antibiotic by injection; take muscle relaxants; take an allergy or cold medicine; take a sleep medicine; or take aspirin-like products or blood thinners.

Other side effects of BOTOX ® Cosmetic include dry mouth; discomfort or pain at the injection site; tiredness; headache; neck pain; and eye problems, including double vision, blurred vision, decreased eyesight, drooping eyelids and eyebrows, swelling of eyelids, and dry eyes.

For more information, refer to the Medication Guide or talk with your doctor.

To report a side effect, please call Allergan Aesthetics at 1-800-678-1605.

Please see BOTOX ® Cosmetic full Prescribing Information , including Boxed Warning and Medication Guide .

References:

  1. Data on File. Allergan, Botulinum Toxin Peer-Reviewed Publications, January 2024 .
  2. Data on File. AbbVie, Neurotoxin Monthly Tracker Report, January 2025 .
  3. Data on File. Allergan, Choosing Botox Quick Quant Study, July 2023
  4. BOTOX ® Cosmetic Prescribing Information, October 2024 .
  5. Dysport ® Prescribing Information, September 2023 .
  6. Xeomin ® Prescribing Information, July 2024 .
  7. Jeuveau ® Prescribing Information, April 2023 .
  8. Daxxify ® Prescribing Information, November 2023 .
  9. Letybo ® Prescribing Information, February 2024
  10. Data on File, Total Number of BOTOX Vials, December 2022
  11. Data on File. Allergan, Neurotoxin Facial Injectables Consumer A&U, 2024.
  12. Data on File. Allergan, BOTOX ® Cosmetic Claims Assessment, April 2023 .

Contact(s)

Investors:
Liz Shea
Liz.Shea@AbbVie.com
(847) 935-2211

Media:
Ember Garrett
Ember.Garrett@allergan.com
(714) 246-3525

© 2025 AbbVie. All rights reserved. BOTOX ® Cosmetic and its designs are trademarks of Allergan Holdings France SAS, and AbbVie company, or its affiliates. All other trademarks are the property of their respective owners.

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/botox-cosmetic-onabotulinumtoxina-unveils-the-one--only-campaign-featuring-real-people-and-their-distinctive-stories-302550142.html

SOURCE AbbVie

News Provided by PR Newswire via QuoteMedia

ABBV
The Conversation (0)
Health Canada Approves AbbVie's RINVOQ®  for the Treatment of Adults with Active Non-Radiographic Axial Spondyloarthritis

Health Canada Approves AbbVie's RINVOQ® for the Treatment of Adults with Active Non-Radiographic Axial Spondyloarthritis

- Approval is based on results from the Phase 3 SELECT-AXIS 2 pivotal clinical trial in which RINVOQ delivered rapid and meaningful disease control, meeting the primary endpoint of ASAS40 response at week 14 versus placebo 1 - RINVOQ is the first and only Janus Kinase (JAK) inhibitor approved to... Keep Reading...
AbbVie Releases New Data Demonstrating Breadth of Its Gastroenterology Portfolio at 2023 Digestive Disease Week®

AbbVie Releases New Data Demonstrating Breadth of Its Gastroenterology Portfolio at 2023 Digestive Disease Week®

- Oral presentations highlight efficacy and safety outcomes from the upadacitinib (RINVOQ ® ) clinical trial program in adults with moderately to severely active Crohn's disease, and investigational use of linaclotide (LINZESS ® ) in treating functional constipation in pediatric patients aged 6... Keep Reading...
Sirona Biochem Announces Exclusive Global Licensing Agreement with Allergan Aesthetics

Sirona Biochem Announces Exclusive Global Licensing Agreement with Allergan Aesthetics

Sirona Biochem Corp . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (" Sirona ") is pleased to announce it has entered into a global exclusive licensing agreement with Allergan Aesthetics, an AbbVie company (NYSE: ABBV), pursuant to which Allergan Aesthetics will develop and commercialize topical skin... Keep Reading...
Canada maple leaves on left and pharmaceutical pills in red and blue on right.

5 Best-performing Canadian Pharma Stocks in 2026

From established players to up-and-coming firms, Canada's pharmaceutical landscape is diverse and dynamic.Canadian drug companies are working to discover, develop and commercialize major innovations amid an increasingly competitive global landscape. Rising technologies such as artificial... Keep Reading...
Stethoscope rests on stacks of US money over a bright blue background.

Eli Lilly to Buy Psychedelics Firm AtaiBeckley for US$2.8 Billion

Pharmaceutical giant Eli Lilly and Company (NYSE:LLY) is pushing further into the psychedelic drug market with a US$2.8 billion buyout of clinical-stage developer AtaiBeckley (NASDAQ:ATAI). The crown jewel of the deal is BPL-003, a clinic-administered nasal spray derived from dimethyltryptamine... Keep Reading...
BriaCell Opens First Canadian Site - Sunnybrook - for Pivotal Phase 3 Trial in Metastatic Breast Cancer

BriaCell Opens First Canadian Site - Sunnybrook - for Pivotal Phase 3 Trial in Metastatic Breast Cancer

Sunnybrook's Odette Cancer Centre, a world-class cancer center in Toronto, Ontario, Canada, joins BriaCell's pivotal Phase 3 clinical trial in metastatic breast cancerBriaCell Phase 3 trial featured in Nature Medicine as one of "Eleven clinical trials that will shape medicine in 2026" briacell... Keep Reading...
BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT

BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT

Arrangement with FUJIFILM Biotechnologies California provides manufacturing capacity for the remainder of BriaCell's pivotal Phase 3 study and commercial scalability potential Bria-IMT is currently being evaluated in Bria-Cell's ongoing pivotal Phase 3 study in metastatic breast cancer briacell... Keep Reading...
BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT

BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT

Charles River Associates (CRA) to evaluate epidemiology, pricing, prescriber dynamics, and market access potential for Bria-IMT in metastatic breast cancer in the USKaleio to support brand strategies and customized commercial-readiness solutionsBria-IMT is currently being evaluated in... Keep Reading...
Syringes with measurement markings overlaid with a fluctuating blue and white line graph.

Zymeworks Expands into Respiratory Market with Theravance Buyout

Oncology-focused drugmaker Zymeworks (NASDAQ:ZYME) has agreed to acquire Theravance Biopharma (NASDAQ:TBPH) for US$929 million in cash, expanding its portfolio into the respiratory segment.The acquisition delivers Zymeworks a 35 percent US net profit share in Yupelri, the first and only... Keep Reading...

Interactive Chart

Latest Press Releases

Related News